INTRODUCTION
Since catheter-based closure of atrial septal defects (ASD) was first reported by King and Mills in 1976 [1] , device occlusion of ASD has been widely adopted. Device occlusion of ASD with the Amplatzer septal occluder (ASO, St. Jude Medical, St. Paul, MN) has demonstrated excellent rates of technical success [2] [3] [4] [5] , and favorable risk of adverse events compared to operative closure [6] [7] [8] . More recently, the Helex septal occluder (HSO, W.L. Gore and Associates, Newark, DE) has shown similarly excellent outcomes [9] [10] [11] [12] . Device erosion, a potentially catastrophic complication of the procedure, has received special attention. Deficient retro-aortic rim has been implicated as a potential risk factor for erosion [13] , raising the question whether it contributes to risk of other adverse events.
The prevalence of deficient retro-aortic rim has been reported as 24% in adults [14] and 59-60% in children [12, 15, 16] . In a single-center case series, retro-aortic rim was not associated with increased risk of technical failure or major early adverse events [15] . However, the study was limited by the sample size and the limited variability in practice of a single center. We sought to address these limitations using data from the IMproving Pediatric and Adult Congenital Treatment (IMPACT V R ) registry. IMPACT V R is the largest clinical registry collecting information on pediatric and adult patients undergoing diagnostic and interventional cardiac catheterization procedures [17] [18] [19] . We performed a retrospective multicenter cohort study to determine if deficient retro-aortic rim was a risk factor for technical failure or major early adverse events. As an exploratory analysis, we also sought to take advantage of this large cohort to identify other risk factors for technical failure and early major adverse events.
METHODS

Data Source
IMPACT
V R is a clinical registry funded by the American College of Cardiology and managed by the National Cardiovascular Data Registry with data from 77 pediatric and general hospitals performing cardiac catheterizations in children and adults with congenital heart disease at the time of this analysis. Participating centers collect information on all patients undergoing cardiac catheterization, including patient demographics, medical/surgical history, procedural information, and adverse events through hospital discharge. Data are recorded using standardized data elements and definitions. The database is subject to rigorous quality assurance standards [20] . Auditing procedures are still being developed [18] . The current study used data from IMPACT v1.0.1. The institutional review board of The Children's Hospital of Philadelphia reviewed the proposed project and determined that it did not represent human subjects research in accordance with the Common Rule (45 CFR 46.102(f)).
Study Population and Study Procedures
The study population was identified by direct query of IMPACT V R by analysts at Mid America Heart Institute. It included subjects of all ages who had an ASD closure procedure recorded in IMPACT V R . Exclusion criteria were multi-fenestrated ASD, additional interventions, and prior cardiac operation, restricting the sample to a homogenous population. Subjects with missing aortic rim data were also excluded from the primary analysis, because the rim measurement was our primary exposure. Several additional analyses were performed to determine whether excluding subjects with missing rim data introduced bias. These analyses are described in the section on statistical analysis.
Data collected included demographics, medical history, details of the ASD anatomy (static defect and septal lengths), hemodynamic data collected (ratio of pulmonary:systemic cardiac index), and details of the procedure (balloon-sizing, anesthesia at start of the case, device used, and presence of a trainee). The primary exposure was defined as deficient retro-aortic rim (aortic rim size <5 mm) and nondeficient retro-aortic rim (!5 mm), as used previously [13, 15, 16, 21] . A primary exposure was chosen before analysis to insure that the distribution of other covariates was uniform between exposed and unexposed groups. Two primary outcomes were identified prior to analysis: technical failure (device malposition requiring re-intervention, embolization requiring re-intervention, residual shunt !3mm, or a device which was deployed, released, and recaptured) and the presence of any early major adverse event (death, cardiac arrest, new arrhythmia, new heart valve regurgitation, tamponade, air embolus, initiation of dialysis, embolic stroke, new extracorporeal membrane oxygenation, new ventricular assist device, unplanned cardiac, vascular, or other surgery, vascular complication requiring treatment, repeat catheterization (all prior to discharge)). For total counts, cases in which multiple technical failures or adverse events were only counted once. Within the primary outcomes, the individual events are also described for completeness' sake. Secondary outcomes were case times (fluoroscopy, sheath, and total case time), which were hypothesized to be surrogates for technical complexity.
Statistical Analysis
Standard descriptive statistics were calculated. Continuous variables were expressed as mean AE standard deviation or median [range and interquartile range (IQR)]. Categorical variables were described as proportions and counts.
For primary and secondary outcomes, hierarchical multivariable models were used to adjust for confounders and clustering by institution. Risk factors for adverse outcome were included in the model without selection criteria based on published series [12, 14, 15, 22] and clinical suspicion. In addition to deficient retro-aortic rim, factors included were subject age, device used, sex, height, trainee present, static ASD diameter, and balloon-sizing technique used. No additional forward or backward selection was used to refine the model. This allowed us to stringently assess the influence of our primary exposure, and in an exploratory fashion to assess other potentially important risk factors. Logistic regression was used to analyze the primary outcomes, while linear regression was used for case times. Post-hoc secondary analyses were performed to investigate if (1) interaction between defect size and deficient retro-aortic rim or (2) inclusion of ratio of static defect size to septal length improved model fit.
An exploratory analysis was performed to determine if the threshold of 5 mm for deficient retro-aortic rim was the most informative. Restricted cubic splines were plotted using methods previously described [23] , estimating odds ratios across the range of retro-aortic rim dimensions to determine if there were other inflection points.
Because of concern raised after the initial analysis about the contribution of device choice on adverse outcomes, two additional analyses were performed: (1) comparing the observed risks of both primary outcomes by device used; and (2) assessing whether technical failure was treated in the initial catheterization, a second catheterization, or in a cardiac operation. Event rates were compared using Chi-square test or Fisher's Exact test as indicated.
Missing data were addressed in several ways. As described above, a significant portion of subjects in the initial query had missing rim measurements. To assess for bias introduced by this choice, baseline characteristics of subjects with missing rim measurements were compared to the study population (Supporting Information  Table S1 ), and sensitivity analyses including this group (with retro-aortic rim measurement coded as missing; Supporting Information Tables S2 and S3 ). For one covariate of clinical interest (balloon-sizing technique), there was a small proportion (1-2%) in whom the data were missing, so a categorical variable for "missing" was added to allow for inclusion of the subjects [24, 25] . For other variables, case elimination was utilized. A threshold for statistical significance was set at p < 0.05. All data analysis was performed using SAS 9.4 (Cary, NC)
RESULTS
Study Population
On initial query, 3,557 ASD closure procedures were performed during the study period. Of these 786 were excluded (156 for multiple ASD, 389 for multifenestrated ASD, 100 for additional procedures, and 141 for prior cardiac operations). Of the remaining 2,771 procedures, 43% (n ¼ 1,207) were missing retroaortic rim measurements, resulting in an analytic cohort of 1,564 procedures from 74 centers (Fig. 1 ). The population with missing rim data was significantly older (p < 0.001), had a higher proportion of adult patients (p < 0.001), had smaller static ASD diameter (p ¼ 0.02), and a higher portion of subjects undergoing ASD closure for stroke prevention and treatment of migraine (p < 0.001; Supporting Information Table S1 ).
The cohort was 36% (n ¼ 564) male and 76% (n ¼ 1184) white. The prevalence of deficient retroaortic rim was 40% (n ¼ 653). 43% of subjects underwent balloon sizing of the ASD. ASO devices were used in 70% of cases (n ¼ 1098), HSO device in 21% (n ¼ 333), and Gore septal occluder or Cardioform device (GSO) in 5% (n ¼ 81).
Differences in demographic, anatomic, and procedural characteristics between subjects with deficient and nondeficient retro-aortic rims are summarized in Table I . The population with deficient retro-aortic rim was younger (median age: 5 years IQR: 4-11 vs. 7 years IQR: 4-15, p < 0.001), had a higher proportion of subjects who were black (p 5 0.02), had shorter total septal length (p < 0.001), and larger balloon-sized defects in the subset who underwent balloon sizing using stretch technique (n ¼ 199, 16.4 AE 5.9 vs. n ¼ 274, 15.3 AE 5.9, p ¼ 0.04). There were no significant differences between groups in static defect diameter (p ¼ 0.4), balloon-sized diameter in the subgroup in whom stop-flow technique was used (p ¼ 0.89), ratio of pulmonary to systemic blood flow (p ¼ 0.4), or the proportion of patients undergoing balloon sizing (p ¼ 0.4). In addition, the choice of (24) a Eighty-seven missing in deficient retro-aortic rim group, 131 missing in the nondeficient rim group.
devices did not differ between subjects with deficient retro-aortic rim and those with larger rims (p ¼ 0.25). Specifically, the ASO device was used in 68% of subjects with deficient retro-aortic rim and 71% of those with larger retro-aortic rims.
Procedural Outcomes
Comparisons of procedural outcomes between the groups are summarized in Table II . Overall, 97% of defects were treated, with no difference in the proportion of subjects treated between those with deficient and larger retro-aortic rims (p ¼ 0.09). In those who underwent attempted device closure, technical failure occurred in 5.8% of all procedures. There was no difference in observed rate of technical failure between subjects with deficient retro-aortic rim (6.7%) and those with larger retro-aortic rim (5.2%, p 5 0.19). Further, there were no differences in the individual risks of device embolization, malposition, residual shunt, or immediate retrieval between the two cohorts.
Embolization of a device occurred in 29 cases, of which 76% were successfully treated by transcatheter intervention. The remaining 24% (n ¼ 6) cases underwent cardiac surgery. One other subject with a malpositioned HSO device underwent cardiac surgery without a subsequent catheterization. For the remaining 61 failure events, the response was not documented (Supporting Information Table S2 ). Major early adverse events occurred in 4.1% of all cases, with no difference in risk observed between subjects with deficient (3.5%) and nondeficient (4.5%, p ¼ 0.34) retroaortic rims. Cardiac arrest, tamponade, unplanned cardiac surgery, and unplanned other surgery were identified before analysis as major early adverse events that could be caused by a device erosion. These occurred in 1.2% of cases with no difference between subjects with deficient retro-aortic rims (n ¼ 8/653, 1.2%) and those with larger retro-aortic rim (n ¼ 11/911, 1.2%, p 5 0.98).
Finally there were no significant differences in observed fluoroscopy (p ¼ 0.11), sheath (p ¼ 0.81), or total case time (p ¼ 0.06) between the two cohorts. 
Multivariate Models
In multivariate models adjusting for pre-specified potential confounders, the risk of technical failure was not significantly higher with deficient retro-aortic rim (OR: 1.32, 95% CI: 0.85-2.05; Table III ). Use of an HSO device was associated with increased risk of technical failure (OR: 1.88, 95% CI: 1.09-3.25). Increasing static ASD size was also associated with increased risk of technical failure (OR: 1.08 for each increase of 1 mm, 95% CI: 1.04-1.12). An increase of 5 mm would be associated with an OR of 1.47.
In a similar multivariate model, deficient retro-aortic rim was not associated with increased risk of major early adverse events (OR: 0.71, 95% CI: 0.41-1.22; Table IV ). Increasing static ASD size was associated with increased risk of adverse event (OR: 1.08 for each increase of 1 mm, 95% CI: 1.03-1.13), while increasing patient height was associated with decreased risk of major early adverse event (OR: 0.87 for each 10 cm, 95% CI: 0.78-0.97).
Sensitivity analyses for models for technical failure (Supporting Information Table S3 ) and major early adverse events (Supporting Information Table S4 ) were performed. The addition of subjects with missing rim data did not significantly change the significance or magnitude of the association between retro-aortic rim size and outcome. There was no significant effect on other risk factors either.
To test if there was significant interaction between deficient retro-aortic rim and defect size, three posthoc analyses were performed. In the first, an interaction term between deficient retro-aortic rim and static defect diameter was added to each model. In the second, an interaction term between deficient retro-aortic rim and a static defect size >10 mm was added to the model. In the third, the ratio of defect size to septal diameter was added as a covariate to the model. None of these additional models altered the magnitude of the odds ratio for the primary outcome (data not shown). Deficient retro-aortic rim was not associated with increased risk of composite outcome (technical failure or major early adverse event; Supporting Information Table S5 ).
After adjusting for covariates, total case time (coefficient: 6.7 min 95% CI: 1.6-11.8, p ¼ 0.01) and fluoroscopy time (coefficient: 1.5 min, 95% CI: 0.2-2.7, p ¼ 0.02) were longer with deficient retro-aortic rim. For sheath time, the point estimate with deficient retro-aortic rim was consistent with a longer time (coefficient: 3.9 min) but the association was not statistically significant (95% CI: À0.3 to 8.0, p ¼ 0.07).
Prespecified secondary analyses were performed to determine whether the widely used definition of a deficient retro-aortic rim (<5 mm) is an effective discriminator for technical failure and adverse events. Splines and accompanying confidence intervals were plotted for the estimated odds ratio of each outcome over the range of retro-aortic rim dimensions. No significant association between the two was found. For technical failure, the spline suggests that 5 mm is a good cut point, as the odds ratio increases at rim sizes below 5 mm and decreases above 5 mm (Supporting Information Fig. S1 ). There was no pattern for major early adverse events (Supporting Information Fig. S2 ).
Effect of Choice of Device on Risk of Technical Failure and Adverse Outcome
The observed risks of technical failure (p ¼ 0.42) were not significantly different by device type (Table  V) , and there were not statistically significant differences in the risk of device deployment, release, and retrieval; embolization; malposition; and residual shunt. However, though not significantly different, the embolization risk for HSO is 3.0%, which is of greater magnitude than the risk in ASO (1.6%), GSO (1.2%), and other devices (1.9%, p ¼ 0.37). Inclusion of subjects with missing device rim measurements does not result in a change in the observed results (Supporting Information Table S6 ).
The observed risk of early major adverse events in subjects undergoing device closure with "Other" devices (9.6%) was subjectively higher than that seen in those receiving ASO (3.7%), HSO (4.5%), or GSO (1.2%, p 5 0.10; Table V) . This difference was not significant. However, the driver for this observation is that there is a significantly higher risk of arrhythmia in the other category (7.7%) compared to the risk in Table S6 ).
DISCUSSION
This multi-center retrospective cohort study assessed the contribution of retro-aortic rim to the risk of technical failure and major early adverse outcome. No significant association was identified between deficient retro-aortic rim and the risk of major early adverse events or technical failure. As exploratory analyses, independent risk factors for adverse events and technical failure were identified. Assessment of the risk of adverse events (such as device erosion) over longer time frames is not possible in the current registry, and for rare events such as device erosion even this large sample remains underpowered.
Though no statistically significant association was seen between deficient retro-aortic rim and the risk of technical failure, there are several factors that suggest such an association may exist: the point estimate in the initial model, the trend seen in the spline, and increased case times in multivariate modeling. The study population was fixed and no power calculations were performed prior to analysis. Even with a large study population there is risk of type II error. In addition, unmeasured confounders may be present, obscuring a more robust association.
Other factors do appear to be more convincingly associated with the risk of technical failure. First, use of the HSO device appears to increase risk of technical failure. There is no guarantee that HSO devices were used in the same situations as ASO devices so caution should be exercised in interpreting this finding, but it does appear that the risk of technical failure is significantly higher with the HSO. No study to our knowledge has previously assessed whether device choice was associated with increased risk of technical failure. A contemporaneous multicenter study from the C3PO registry did not address differences in device type [26] . Post hoc analysis of the observed risk of adverse events to explore this issue demonstrated a suggestive but not significant increase in the risk of embolization with HSO. The change in risk was not associated with a higher rate of deploying, releasing, and retrieving HSO relative to other devices. Each component of technical failure is rare enough that multivariate analysis is not possible.
Second, increasing defect size was associated with increased risk of technical failure. Case series have described closing large defects in both adults and children [27, 28] . The only study to our knowledge that addresses risk factors for these outcomes including other covariates was restricted to small children and did not identify defect size as a significant risk factor [12] . Post-hoc analyses were attempted to explore the effect of defect size relative to retro-aortic rim size but these did not reveal a significant interaction.
In contrast to technical failure, there were no indications that retro-aortic rim dimension and the risk of major early adverse events was associated. This was true in a sub-analysis of events consistent with early device erosion as well as a broader collection of major early adverse events. In terms of other covariates, increasing patient height was associated with decreased risk and increasing defect size was associated with increased risk of a major adverse event. This combination of risks should be considered when discussing with patients the relative risks and benefits of transcatheter and operative closure of ASD. A potential concern raised by this analysis is that the rates of technical failure and major early adverse event rates are higher than previously reported [2, [4] [5] [6] [9] [10] [11] 14, 15, 26, [29] [30] [31] . Definitions of technical failure and major early adverse outcomes were chosen to be sensitive. For technical failure, many of the included outcomes can be addressed with repeat catheterization which has been accomplished without significant harm to the patient and while maintaining a cost advantage to device closure [32] . Several of the adverse outcomes are redundant with technical failure as described above (e.g., repeat catheterization). In addition, new arrhythmia, which accounted for 48% of adverse outcomes, includes transient rhythm disturbances, which are of lesser severity than the other listed outcomes. An alternative explanation arises from the fact that previous studies are from large centers with significant experience or in clinical trials, while the current study reports outcomes from a cross-section of current practice. This is supported by a recent multicenter case series from the C3PO registry, which reports similarly high risk for new arrhythmia (2.4 vs. 2.0% in the current series), embolization (1.5 vs. 1.9% in this series), and major adverse events (4.7 vs. 4.1% in this series) [26] . It is important to emphasize that in series with simultaneous measurement of adverse outcomes between surgical and device closure of ASD, transcatheter closure has performed at least as well as surgery regardless of the era in which data were recorded [2, 8, 31, 32] .
Inclusion of residual shunt !3 mm as technical failure may be controversial to some. Allowing for small residual shunts may allow for the use of a relatively small device, with the theoretical benefit of reducing the risk of contact between device and atrial wall and reduced risk of device erosion. In addition, the risk of a residual shunt must be weighed against the risk of placing a second device and/or operative closure. Some centers including our own who have not aggressively over-sized devices have reported relatively higher risk of trivial (<1 mm) shunt (10% in a review of our center's experience) and that many of these small shunts resolve over time [15] . However, in that series, there were no larger residual shunts, and, to our knowledge, there is not published data on the natural history of larger residual shunts. This may be worth describing in future studies.
The optimal strategy in addressing a patient with an ASD with deficient retro-aortic rim remains a challenge. It is an extremely common anatomic variant [12, 14, 15] , which was confirmed in this study. It does not appear to increase the risk of early major adverse events with device closure, but the concern for longerterm risks (particularly device erosion) persists. It does appear, however, that 5 mm remains an appropriate cut-point to distinguish between the "deficient" and "sufficient" retro-aortic rim for the outcomes we can measure; we were not able to identify a cut-point with improved discrimination for these outcomes. Interestingly, despite the attention that the risk of device erosion with ASO devices has received, device choice was not different between subjects with deficient and larger retro-aortic rims. In its current iteration, the IMPACT Registry could not be used to assess long term risks following transcatheter device deployment. The registry contains outcome data until hospital discharge. To study questions about longer-term outcomes, addition of a module to IMPACT that allows for longer-term follow-up or linkage of the IMPACT registry to other datasets is necessary.
Limitations
We acknowledge that there are limitations to this study. A significant minority of the potential study population was excluded because the retro-aortic rim dimension was not recorded. These subjects were excluded because they did not have information about the primary exposure for our study. In addition, as noted earlier, the population with missing rim data was older, with a larger proportion of adult patients, smaller defects, and a higher proportion undergoing closure of ASD for stroke and migraine, suggesting they include a subgroup with qualitatively different defects than those with reported rim measurements. In addition, sensitivity analyses including these subjects in multivariate models did not result in changes in the major findings of the study (Supporting Information  Tables S2 and S3 ), except that in the case of the HSO device the increased risk for technical failure was no longer significant. Additionally, as a retrospective study, the population was fixed, and there is a risk of type II error. Post-hoc power calculations have been shown to be a potential source of bias [33] . We have included confidence intervals where appropriate to provide the reader the opportunity to interpret whether effect sizes reported are appropriate. The IMPACT V R Registry contains self-reported data, and as of this time, auditing procedures have not been implemented. This introduces possible information bias, which, it should be noted, is likely to bias results towards the null. The current cohort only contains the results of subjects referred for transcatheter ASD closure, and is not able to address the comparable results in similar populations referred to operative ASD closure. The results of operative ASD closure in comparison to transcatheter ASD closure have been reported previously [2, 8, 10, 32, 34, 35] . However, in the current era, there have not been reports about the effect that concern about deficient retro-aortic rim has had on physician and family choice between operative and transcatheter ASD closure.
CONCLUSION
Accepting these limitations, we conclude that deficient retro-aortic rim is highly prevalent. There was not a significant association between deficient retroaortic rim and technical failure or major early adverse events. Other covariates independently associated with these outcomes were identified. Studying longterm risk of adverse outcomes is important, but cannot be accomplished with the current design of the registry.
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